ArticleBMC infectious diseases2026
Diagnostic and treatment delays and associated factors among RR-TB patients under molecular drug susceptibility testing: a retrospective study in Guizhou Province, China.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Changing epidemiological patterns of tuberculosis in China from 1990 to 2023: trends and future projections of drug-resistant and HIV-associated tuberculosis.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundRifampicin-resistant tuberculosis (RR-TB) constitutes a persistent and formidable challenge for global TB control programs, as delayed diagnosis and treatment initiation contribute to transmission and poor outcomes. Molecular drug susceptibility testing (mDST) enables rapid detection of resistance and may shorten these delays. This study evaluated the impact of mDST on diagnostic and treatment delays among RR-TB patients in Guizhou Province, China, and explored factors associated with delays under mDST.
methodAll RR-TB cases registered in Guizhou between January 2019 and December 2023 were included. Patients were classified into the mDST or phenotypic DST (pDST) groups. Diagnostic delay was defined as the primary outcome, and treatment initiation delay as the secondary outcome. Diagnostic and treatment delays were compared using chi-square and Mann–Whitney U tests. Multivariable logistic regression identified predictors of diagnostic delay, including time-varying effects, and treatment delays in the mDST group.
resultAmong 2,661 RR-TB patients, 93.3% were diagnosed using mDST. The overall median diagnostic delay was 15 (2–62) days, significantly shorter in the mDST group than in the pDST group [14 (2–49) vs. 57 (1–164) days; Z = − 4.262, P < 0.001]. The diagnostic delay rate was lower with mDST group than in the pDST group (48.3% vs. 56.8%; [Formula: see text]= 6.701, P = 0.010). Time-interaction analysis showed that the diagnostic delay associated with pDST was pronounced during 2019–2021 but attenuated over time (Pinteraction = 0.003). In the mDST group, having comorbidities (OR = 1.56, P = 0.013) were associated with diagnostic delay, while patients detected through seeking consultations (OR = 1.47, P < 0.001) or follow-up (OR = 1.35, P = 0.004) were more likely to experience delay than those referred from other facilities. Among 2,508 patients who initiated treatment, the median time to treatment was 5 (0–22) days, significantly shorter in the mDST group than in the pDST group [4 (0–20) vs. 14 (0–91) days; Z = − 6.045, P < 0.001]. A higher proportion of mDST patients began treatment within 5 days (52.9% vs. 41.3%; [Formula: see text]= 10.917, P < 0.01). In the mDST group, intra-city mobility (OR = 1.64, P = 0.038) and diagnosis at county-level hospitals (OR = 1.97, P = 0.008) predicted treatment delay.
conclusionLarge-scale implementation of mDST substantially shortened diagnostic and treatment initiation intervals for RR-TB patients in Guizhou Province. However, delays persisted among ethnic minorities, intra-city migrants, and patients diagnosed at county-level facilities. Strengthening diagnostic-to-treatment referral pathways and expanding mDST access in under-resourced areas are essential to further improve the RR-TB care continuum in high-burden settings. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.